ScholarIQanswers from OpenAlex & ORCID
Grace Kong
ResearcherPublications, citations & collaboration network
Grace Kong is a researcher indexed in ScholarIQ from OpenAlex & ORCID.
How many works does Grace Kong have?
ScholarIQindexed works
Grace Kong has 153 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does Grace Kong have?
ScholarIQcitation count
Grace Kong has 6,962 citations in the OpenAlex counts ScholarIQ stores.
What is the h-index of Grace Kong?
ScholarIQh-index
Grace Kong has an h-index of 40 in OpenAlex.
What is the i10-index of Grace Kong?
ScholarIQi10-index
Grace Kong has an i10-index of 75 in OpenAlex.
What is the ORCID of Grace Kong?
ScholarIQorcid
The ORCID for Grace Kong is on the source record.
What is the OpenAlex record for Grace Kong?
ScholarIQopenalex
The OpenAlex for Grace Kong is on the source record.
What are the most-cited papers on Grace Kong?
ScholarIQmost cited works
[177Lu]-PSMA-617 radionuclide treatment in patients with metastatic castration-resistant prostate cancer (LuPSMA trial): a single-centre, single-arm, phase 2 study
Michael S. Hofman, John Violet, Rodney J. Hicks, Justin Ferdinandus, Sue Ping Thang, Tim Akhurst, Amir Iravani, Grace Kong, Aravind Ravi Kumar, Declan G. Murphy, Peter Eu, Price Jackson, Mark Scalzo, Scott Williams, Shahneen Sandhu
Dosimetry of <sup>177</sup>Lu-PSMA-617 in Metastatic Castration-Resistant Prostate Cancer: Correlations Between Pretherapeutic Imaging and Whole-Body Tumor Dosimetry with Treatment Outcomes
John Violet, Price Jackson, Justin Ferdinandus, Shahneen Sandhu, Tim Akhurst, Amir Iravani, Grace Kong, Aravind Ravi Kumar, Sue Ping Thang, Peter Eu, Mark Scalzo, Declan G. Murphy, Scott Williams, Rodney J. Hicks, Michael S. Hofman
Long-Term Follow-up and Outcomes of Retreatment in an Expanded 50-Patient Single-Center Phase II Prospective Trial of <sup>177</sup>Lu-PSMA-617 Theranostics in Metastatic Castration-Resistant Prostate Cancer
John Violet, Shahneen Sandhu, Amir Iravani, Justin Ferdinandus, Sue-Ping Thang, Grace Kong, Aravind Ravi Kumar, Tim Akhurst, David A. Pattison, Alexis Beaulieu, Jennifer Mooi, Ben Tran, Christina Guo, Victor Kalff, Declan G. Murphy, Price Jackson, Peter Eu, Mark Scalzo, Scott Williams, Rodney J. Hicks, Michael S. Hofman
PSMA and FDG-PET as predictive and prognostic biomarkers in patients given [177Lu]Lu-PSMA-617 versus cabazitaxel for metastatic castration-resistant prostate cancer (TheraP): a biomarker analysis from a randomised, open-label, phase 2 trial
James P Buteau, Andrew Martin, Louise Emmett, Amir Iravani, Shahneen Sandhu, Anthony M. Joshua, Roslyn J. Francis, Alison Y. Zhang, Andrew M. Scott, Sze-Ting Lee, Arun Azad, Margaret McJannett, Martin R. Stockler, Scott Williams, Ian D. Davis, Michael S. Hofman, Michael S Hofman, Tim Akhurst, Ramin Alipour, Arun A Azad, Patricia Banks, Alexis Beaulieu, James P Buteau, Wei Chua, Ian D Davis, Nattakorn Dhiantravan, Louise Emmett, Kate Ford, Michael S Hofman, Michael S Hofman, Roslyn J Francis, Craig Gedye, Jeffrey C. Goh, Alex Guminski, Anis Hamid, Mohammad B. Haskali, Rodney J. Hicks, Edward Hsiao, Amir Iravani, Anthony M Joshua, Ian Kirkwood, Grace Kong, Edmond M. Kwan, Ailsa Langford, Nicola Jane Lawrence, Sze-Ting Lee, Jeremy Lewin, Peter Lin, Andrew J Martin, William M. McDonald, Margaret M McJannett, Kate Moodie, Declan G. Murphy, Siobhan Ng, David A. Pattison, Izabella Pokorski, Shakher Ramdave, Aravind S. Ravi Kumar, Andrew Redfern, Natalie Rutherford, Javad Saghebi, Shahneen Sandhu, Andrew M Scott, Lavinia Spain, Martin R Stockler, Shalini Subramaniam, Thean Hsiang Tan, Sue Ping Thang, Ben Tran, Roslyn E. Wallace, Andrew Weickhardt, Scott G Williams, Sonia Yip, Alison Y. Zhang
High management impact of Ga‐68 DOTATATE (GaTate) PET/CT for imaging neuroendocrine and other somatostatin expressing tumours
Michael S. Hofman, Grace Kong, Oliver Neels, Peter Eu, Emily Hong, Rodney J. Hicks